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Abstract
Background: Previous studies from our group have shown that a high prevalence of vertebral
deformities suggestive of fracture can be found in patients with an inflammatory disease, despite a
near normal bone mineral density (BMD). As quantitative ultrasound (QUS) of the heel can be used
for refined assessment of bone strength, we evaluated whether QUS can be used to identify
subjects with an inflammatory disease with an increased chance of having a vertebral fracture.
Methods: 246 patients (mean age: 44 ± 12.4 years) with an inflammatory disease (sarcoidosis or
inflammatory bowel disease (IBD)) were studied. QUS of the heel and BMD of the hip (by dual X-
ray absorptiometry (DXA)) were measured. Furthermore lateral single energy densitometry of the
spine for assessment of vertebral deformities was done. Logistic regression analysis was performed
to assess the strength of association between the prevalence of a vertebral deformity and BMD and
QUS parameters, adjusted for gender and age.
Results: Vertebral deformities (ratio of <0.80) were found in 72 vertebrae of 54 subjects (22%).
In contrast to the QUS parameters BUA (broadband ultrasound attenuation) and SOS (speed of
sound), T-score of QUS and T-scores of the femoral neck and trochanter (DXA) were lower in
the group of patients with vertebral deformities. Logistic regression analysis showed that the
vertebral deformity risk increases by about 60 to 90% per 1 SD reduction of BMD (T-score)
determined with DXA but not with QUS.
Conclusion: Our findings imply that QUS measurements of the calcaneus in patients with an
inflammatory condition, such as sarcoidosis and IBD, are likely of limited value to identify patients
with a vertebral fracture.
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Background
Osteoporosis is a skeletal disease characterized by low
bone mass and microarchitectural deterioration resulting
in increased bone fragility and hence susceptibility to frac-
ture [1,2]. The benchmark for the diagnosis of osteoporo-
sis is the assessment of bone mineral density (BMD) with
dual energy X-ray absorption (DXA) [2], as it is well estab-
lished that the risk of future fracture rises with the decline
of BMD. However, low BMD alone is not the only deter-
minant of fracture risk [3] and it is evident that assessment
of fracture risk should encompass all aspects of risk and
not be guided exclusively by results of bone mineral den-
sity measurements [4]. In addition, in several conditions
BMD evaluation provides a modest prediction of fracture
risk. For example, the use of glucocorticoids (GCs) is a
substantial risk factor for future fractures, which is largely
independent of BMD [5,6].
We reported recently that a high prevalence of vertebral
deformities suggestive of fracture can be found in patients
who are considered at risk for secondary osteoporosis due
to an inflammatory disease, such as sarcoidosis and
inflammatory bowel disease (IBD), despite a near normal
BMD [7]. This may imply that bone strength is decreased
in patients with inflammatory diseases, and that changes
in bone microarchitecture rather than low BMD result in
an increased fracture risk [8,9].
The last years there has been increasing interest in Quan-
titative Ultrasound (QUS) methods for refined assess-
ment of bone strength [10]. This noninvasive technique
may assess microarchitecture and elasticity in addition to
bone mineral density [11]. Several studies have demon-
strated that QUS of the heel can predict fracture compara-
ble to and independent of spine and femur BMD, and that
it can be used to identify patients with higher risk [12-15].
Compared with DXA, QUS is less expensive, portable,
does not require specially trained personnel and does not
employ ionizing radiation.
To evaluate whether QUS can indeed be used to identify
subjects likely to have a vertebral fracture irrespective of
changes in BMD, we performed QUS on our series of sub-
jects with sarcoidosis and IBD [7] and compared the
results with results of vertebral fracture assessment and
BMD measurements with DXA.
Subjects and methods
Patients
Between January 2002 and July 2003, all patients with
inflammatory bowel disease or sarcoidosis who had a dis-
ease duration of at least one year, and attended the outpa-
tient clinic of the University Hospital Maastricht, were
asked to participate in this cross-sectional study. Sixteen
patients with known causes of bone mass abnormalities,
such as renal failure, thyroid dysfunction, alcoholism,
long-term anticoagulant use and ankylosing spondylitis
were excluded. Thirty-six patients were excluded because
of the use of bisphosphonates or hormone replacement
therapy.
Finally, 246 patients were included (mean age: 44 ± 12.4
years) of which 87 were diagnosed with sarcoidosis and
159 with inflammatory bowel disease. All patients were
Caucasians and diagnosed with sarcoidosis according to
the WASOG guidelines [16], based on consistent clinical
features and results of an analysis of bronchoalveolar lav-
age fluid [17] or with CD (n = 95) or UC (n = 64) on clin-
ical grounds using endoscopic and/or radiological
evidence, and by histological investigation of mucosal
biopsies and/or surgical specimens when available. For
confirmation of the CD diagnosis the Lennard-Jones crite-
ria [18] and for UC the Truelove and Witts criteria [19]
were applied.
Table 1: Demographic, treatment variables and clinical risk factors in the study patients (n = 246).
Variable Total group (n = 246)
Age (years) 44 ± 12.4
Males/premenopausal women/postmenopausal women 109/103/34 (44/42/14)
Body mass index (kg/m2) 25.5 ± 4.7
Sarcoidosis/CD/UC 87/95/64 (35/39/26)
Disease duration (years) 6 (1–36)
GC use never/previous/current 74/124/48 (30/50/20)
Daily dose GC current group 12.9 (2.5–39)
Fracture > 50 years, number 2/83 (2)
Vertebral deformity by DXA 54 (22)
Low body weight (< 60 kg) 44 (18)
Low physical activity index ≤ 5 53 (22)
Mother with hip deformity 16 (7)
Data are given as mean ± SD, median (range) or number (%). Abbreviations: CD, Crohn's disease; UC, ulcerative colitis; GC, glucocorticoid; DXA, 
dual-energy X-ray absorptiometry.BMC Musculoskeletal Disorders 2008, 9:72 http://www.biomedcentral.com/1471-2474/9/72
Page 3 of 7
(page number not for citation purposes)
The clinical records of all patients were reviewed. Demo-
graphic, clinical and treatment data of these patients are
summarized in table 1. No patients were on bisphospho-
nates.
Patients were evaluated according to a standard protocol
that included questionnaires related to known clinical risk
factors for osteoporosis (weight below 60 kg, hip fracture
in the mother, history of fractures after age 50, menopau-
sal status and severe immobilization) [20], calcium
intake, physical activity [21], measurement of height and
weight and measurement of BMD. Glucocorticoid therapy
was evaluated by means of a patient questionnaire and
verified using all the records of the patient's pharmacist.
Informed consent was obtained from all participants and
this study was approved by the ethical committee of the
hospital.
Bone mineral density and morphometry
QUS and DXA measurements were performed. QUS was
performed in the left calcaneus using a Sahara device
(Hologic, Waltham, MA, USA). This equipment measures
the broadband ultrasound attenuation (BUA) (dB/MHz)
and the speed of sound (SOS) (m/sec) in a fixed region of
interest in the central calcaneal zone. The device combines
the values of BUA and SOS to yield a parameter known as
the "quantitative ultrasound index" (QUI) or stiffness,
based on the following equation: QUI = 0.41 * (BUA +
SOS) -571. The QUI is also expressed as a T-score (refer-
ence data were those provided by the manufacturer). The
heel of each patient was measured three times with com-
plete repositioning between measurements. The definitive
result was the mean of these three measurements. The
coefficient of variation (CV) of the QUI was 1.4%. The
instrument was subjected to daily quality control using a
phantom provided by the manufacturer.
BMD of the hip was measured by dual energy X-ray
absorption (DXA, Hologic QDR 4500, NHANES-III refer-
ence group). The hip was measured in the standard pro-
jection, and results are reported for femoral neck and
trochanter. Standard procedures supplied by the manufac-
turer for scanning and analysis were performed. Calibra-
tion with the manufacturer's spine phantom and quality
control analysis was performed daily. The CV for BMD
measurements was 1.0 %. Furthermore, after bone density
measurement a lateral single energy densitometry of the
thoracic and lumbar spine for vertebral fracture assess-
ment (VFA) was performed (also called Morphometric X-
ray absorptiometry (MXA)) [22]. The scans obtained were
analyzed twice by one trained operator (BD) (intra-
observer coefficient of variation: 0.85), using the quanti-
tative method of Genant [23]. The observer was blinded
to the T-score values and to the values of the first set of
measurements. After visual examination six points were
placed on each vertebral body from T4 to L4. From these
points three vertebral heights were measured anterior
(Ha), mid (Hm) and posterior (Hp); On the basis of the
average score of these morphometric measurements ratios
were calculated and a prevalent vertebral deformity was
defined as a reduction of height of 20 % or more (Ha/Hp;
Hm/Hp and Hp/Hp below) [23]. Severity of deformities
was assessed according to the method of Genant [23]. A
score of '0' was assigned to normal, non-fractured verte-
bra; '1' for a mild deformity (20–25% reduction in ante-
rior, middle or posterior vertebral height); '2' for a
moderate deformity (25–40% reduction) and '3' for a
severe deformity (>40% reduction).
Statistical analysis
Student t-tests, chi-square tests, and one-way ANOVAs
were used, depending on the variables and subgroups
tested. Logistic regression analyses was performed to
assess the strength of association between the prevalence
of a vertebral deformity (dependent variable) and BMD
and QUS parameters (BMD femoral neck or  BMD tro-
chanter or QUI), adjusted for gender and age (covariates).
A p-value < 0.05 was considered statistically significant.
Analyses were performed with SPSS version 12.0.
Results
As summarized in table 1, our series consisted of 103 pre-
menopausal women, 34 post-menopausal women, and
109 men. The mean age (± SD) of this group of patients
was 44 ± 12.4 years and this was similar in both sarcoido-
sis and IBD. With QUS, the broadband ultrasound atten-
uation (BUA) value was higher in men than in women (78
± 16 versus 73 ± 15 dB/MHz, p < 0.005). No differences
between the sexes of the other QUS parameters were
found. The T- or Z-scores of FN or trochanter determined
with DXA were not different between the sexes as well.
T-scores of femoral neck and/or trochanter determined
with DXA were in the osteopenic (T-score < -1 and > -2.5)
or osteoporotic (≤ -2.5) range in respectively 50% and 2%
of the patients studied, in total in 52%. In contrast, QUS
of the calcaneus revealed a T-score below -1 in 32% of the
patients. Correlations between DXA and QUS T-scores
were r = 0.35 for the T-score of the quantitative ultrasound
index (QUI) with the T-score of the femoral neck (p <
0.001) (figure 1) and r = 0.36 for the T-score QUI with the
T-score of the trochanter (p < 0.001).
Clinical non-vertebral fractures had occurred in two post-
menopausal women. Vertebral deformities with VFA
(ratio of < 0.80) were found in 72 vertebrae of 54 subjects
(22%) with a higher prevalence in men (32%) than in
women (14%). Sixty-one of these were wedge and 9
biconcave deformities. Two crush deformities were seen.
Multiple vertebral deformities were observed in 6% of theBMC Musculoskeletal Disorders 2008, 9:72 http://www.biomedcentral.com/1471-2474/9/72
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T-score Femoral neck (DXA) versus T-score QUI (QUS) Figure 1
T-score Femoral neck (DXA) versus T-score QUI (QUS). DXA, dual energy X-ray absorption; QUI, quantitative ultra-
sound index; QUS, quantitative ultrasound; IBD, inflammatory bowel disease.
Table 2: Bone variables in patients with and without any vertebral deformity, measured morphometrically.
Without deformity (192) With any deformity (54) All P*
DXA variables
Femoral neck (g/cm2) 0.80 ± 0.12 0.76 ± 0.10 0.79 ± 0.11 0.006
• T-score -0.66 ± 0.9 -1.16 ± 0.8 -0.77 ± 0.9 <0.001
• Z-score -0.13 ± 1.0 -0.43 ± 0.9 -0.20 ± 1.0 0.06
Trochanter (g/cm2) 0.72 ± 0.13 0.69 ± 0.10 0.71 ± 0.13 0.2
• T-score -0.21 ± 1.0 -0.51 ± 0.8 -0.27 ± 1.0 0.04
• Z-score 0.05 ± 1.1 -0.16 ± 0.8 0.00 ± 1.0 0.2
QUS variables
BUA (dB/MHz) 76 ± 16 73 ± 14 75 ± 16 0.2
SOS (m/s) 1545 ± 89 1531 ± 99 1542 ± 92 0.3
QUI 103 ± 45 94 ± 16 101 ± 41 0.1
T-score -0.34 ± 1.1 -0.65 ± 0.9 -0.41 ± 1.0 0.04
Data are given as mean ± SD or number (%); * p between patients with and without vertebral deformity;
Abbreviations: DXA, dual energy X-ray absorption; QUS, quantitative ultrasound; BUA, broadband ultrasound attenuation; SOS, speed of sound; 
QUI, quantitative ultrasound index.BMC Musculoskeletal Disorders 2008, 9:72 http://www.biomedcentral.com/1471-2474/9/72
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entire cohort and 7% had one or more moderate or severe
deformities.
In table 2 data of BMD measurements with DXA and QUS
in the group of patients with or without vertebral deform-
ities are summarized. Relative to the patients without ver-
tebral deformities, those with vertebral deformities were
on average older. The former group comprised more
women, the latter more men. T-scores but not Z-scores of
the femoral neck and trochanter (DXA) were lower in the
group of patients with vertebral deformities. The T-score
of the calcaneus (QUS) was also lower in this group of
patients. No differences for the other ultrasound parame-
ters were found between the groups with or without verte-
bral deformities. Furthermore, no differences were found
in clinical risk factors, for the different diseases, GC use,
disease duration, BMI, physical activity, calcium intake,
current use of calcium and/or vitamin D supplements,
aminosalicylates, immunosuppressive medication, and
budenoside.
Table 3 gives odds ratios (OR) per unit T-score reduction
(per SD) for any vertebral deformity for the three separate
regression analyses. The vertebral deformity risk increases
by about 60 to 90% per 1 SD reduction determined with
DXA but not with QUS. When both BMD of the femoral
neck and QUI are entered simultaneously in the regres-
sion analysis the respective OR's are 1.81 (1.18 – 2.75, p
= 0.006) for BMD-FN and 1.09 (0.77 – 1.56, p = 0.623)
for QUI.
Discussion
Our study shows that in a group of patients with an
inflammatory disease as sarcoidosis and inflammatory
bowel disease (IBD) none of the QUS variables had added
value to recognize patients with a prevalent vertebral
deformity suggestive of fracture.
In several other studies QUS has been compared with
DXA in patients with IBD. Robinson and coworkers [24]
studied 100 patients with Crohn's disease (CD) and 52
age-matched controls and found lower values of both
BUA and SOS in CD. The correlation between BUA and
BMD-values determined at the hip and spine with DXA
was, however, insufficient to recommend QUS as a
screening tool. In another study, 53 patients with CD and
57 with ulcerative colitis (UC) were included and QUS
variables (BUA and SOS) were compared with DXA-meas-
urements of the hip and lumbar spine [25]. Although this
study also revealed a correlation between the QUS varia-
bles and DXA (r = 0.50 to 0.67), the agreement between
measurements in individual patients was poor. Similar
observations were made in two other studies on patients
either with CD or UC [26,27]. No studies with QUS have
been performed in patients with sarcoidosis.
A shortcoming of all the reported studies on the value of
QUS in IBD is of course that they used BMD determined
by DXA as gold standard, assuming that fracture risk
increases with a decrease in BMD as in subjects without
inflammatory conditions. No assessment of clinical and
prevalent vertebral fractures was done. In our series, verte-
bral deformities suggestive of non-clinical fractures were
found in 22% of patients. The T-scores of these patients
determined by both DXA and QUS were on average lower
than those in patients without vertebral deformities.
Although there was a correlation between T-scores deter-
mined with QUS and DXA, this correlation was moderate,
as found by others [28]. In addition, the calculated Odds
ratios for any vertebral deformity per unit T-score reduc-
tion was increased for BMD of the hip (DXA) but not for
the QUI of the calcaneus. This supports the view that the
predictive value of QUS in patients with inflammatory
conditions is poor. On the other hand, a limitation of our
series is the moderate number of patients with one or
more deformities suggestive for vertebral fracture. It is
therefore possible that our study did not have adequate
power to delineate an association between QUS and ver-
tebral fractures.
Our findings are in contrast with several large prospective
studies that have shown that QUS of the calcaneus can
predict fracture risk nearly as good as DXA [12-14]. These
studies are, however, all studies in elderly women and
involve prediction of clinical (mainly non-vertebral) frac-
tures. Kanis explored the relationship between QUS-deter-
minations at the phalanges with age and the probability
of symptomatic vertebral fractures and concluded that the
10-year probability of clinical vertebral fractures above
the age of 45 increased for each SD decrease in measure-
ment of SOS and fast wave amplitude (RR 1.7, respectively
2.4/SD) [29]. Studies on morphometric vertebral deform-
ities and QUS parameters are, however, scarce. In 764
postmenopausal women (mean age 73 ± 6.4 years) the
prevalence of nontraumatic vertebral fractures assessed
with DXA was compared with an age matched control
group with normal morphometry and this study showed
that heel QUS enabled discrimination of women with
Table 3: Odds ratios* for any vertebral deformity of various bone 
measurements adjusted for gender and age in patients with an 
inflammatory disease
OR 95 % CI P
BMD femoral neck 1.88 1.26–2.81 0.002
BMD trochanter 1.63 1.12–2.37 0.01
QUI 1.31 0.95–1.81 Ns
Abbreviations: OR, odds ratio; CI, confidence interval; BMD, bone 
mineral density; QUI, quantitative ultrasound index.
* OR per one unit T-score reduction (per SD)BMC Musculoskeletal Disorders 2008, 9:72 http://www.biomedcentral.com/1471-2474/9/72
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fracture from those without [30]. The same findings were
reported in another study in postmenopausal women
with rheumatoid arthritis [31]. On the other hand, other
studies revealed no differences in patients with and with-
out a prevalent vertebral deformity. In one cross-sectional
study in 551 post-menopausal women (mean age 65.2 ±
13.1) receiving chronic glucocorticoid therapy a high
prevalence of asymptomatic morphometric vertebral frac-
tures was found (37%), without any difference in QUS
measurements between patients with and without
deformities [32]. This indicates that if QUS may be of any
value to predict fracture risk, this will be in postmenopau-
sal women and not in the type of patients included in our
study.
Although the T-scores of patients with vertebral deformi-
ties of our series were lower than in those without, the Z-
cores were not different. This means that the differences in
T-score are likely due to differences in age rather than dif-
ferences in disease activity. In addition, despite the fact
that the T-scores were lower, they were certainly not diag-
nostic for osteoporosis, indicating that in inflammatory
conditions, an increased fracture risk is due to changes in
bone strength that are not combined with changes in
BMD [7].
Conclusion
In our hands QUS measurements of the calcaneus in
patients with an inflammatory condition, such as sar-
coidosis and IBD, were not associated with prevalent ver-
tebral deformities and are therefore likely not of value to
recognise patients at risk for fracture. Hence, we feel that
both BMD measurement with DXA and vertebral fracture
assessment are better methods to identify such patients.
Follow-up studies are, however, needed to substantiate
this view.
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